
Maggie Fick
European Pharmaceuticals Industry Correspondent at Reuters
European Pharmaceuticals Industry correspondent @Reuters. Previously reporting from Africa and the Middle East for @Reuters @FT @AP since 2010.
Articles
-
1 month ago |
reuters.com | Jacob Gronholt-Pedersen |Maggie Fick
Danish businessman Lars Rebien Sorensen, former CEO of Novo Nordisk for 16 years and current chair of the Novo Nordisk Foundation, who joins the board of Novo Nordisk A/S as an observer, poses in this handout image released on January 31, 2023.
-
1 month ago |
jp.reuters.com | Maggie Fick
デンマークの製薬大手ノボノルディスクは16日、ラース・ヨルゲンセン最高経営責任者(CEO)が退任すると発表した。写真は2024年5月、ペンハーゲンで撮影(2025年 ロイター/Tom Little) [コペンハーゲン 16日 ロイター] - デンマークの製薬大手ノボノルディスク(NOVOb.CO), opens new tabは16日、ラース・ヨルゲンセン最高経営責任者(CEO)が退任すると発表した。後任が決まるまではCEO職にとどまる。 広報担当者によると、投資部門を通じて同社の経営権を握るノボノルディスク財団が今年4月の会合でヨルゲンセン氏の早期退任を要求した。 ヨルゲンセン氏の指揮下で肥満症治療薬の「ウゴービ」と「ゼップバウンド」の販売が大きく伸び、収益性の高い肥満症治療薬市場で快走したものの、今後は優位性が失われることが懸念されている。 同社の株価は昨年6月に過去最高値を付けた後、大きく下落している。特に米同業イーライリリー(LLY.N), opens new...
-
1 month ago |
wdez.com | Patrick Wingrove |Maggie Fick
By Patrick Wingrove and Maggie Fick(Reuters) -As Denmark’s Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters. Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
-
1 month ago |
wmbdradio.com | Patrick Wingrove |Maggie Fick
By Patrick Wingrove and Maggie Fick(Reuters) -As Denmark’s Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters. Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
-
1 month ago |
whbl.com | Patrick Wingrove |Maggie Fick
By Patrick Wingrove and Maggie Fick(Reuters) -As Denmark’s Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters. Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 22K
- Tweets
- 13K
- DMs Open
- Yes

RT @specialreports: Health workers killed in the Gaza war have included more than 50 highly qualified specialists, @Reuters found; doctors…

RT @Reuters: .@Reuters chronicled the struggle of Dr. Sireen Al-Attar, an obstetrician-gynecologist, and two other specialist doctors in Ga…

RT @Reuters: Dr. Sireen Al-Attar was on WhatsApp day and night, communicating with colleagues and pregnant women in Gaza to make childbirth…